Which peptides show up most in weight-loss research? A ranked reference from the strongest published-literature profiles to the more experimental candidates.
This reference summarises which peptides carry the strongest published research profile for weight-related endpoints, evaluated by depth of clinical-trial literature, mechanistic clarity, and analytical characterisation.
- Retatrutide — triple GIP/GLP-1/GCG agonism, strongest published Phase II weight-loss magnitude.
- Tirzepatide — dual GIP/GLP-1 agonism, deep SURPASS/SURMOUNT literature.
- Semaglutide — GLP-1 mono-agonism, most extensively documented long-term dataset.
- Cagrilintide — long-acting amylin analog, frequently paired with semaglutide in research.
- AOD-9604 — lipolytic hGH fragment; short half-life and narrower published dataset.
- 5-Amino-1MQ — small-molecule NNMT inhibitor; pre-clinical adipocyte research.
How to read the ranking
Depth of literature does not imply superiority in every research context. A short-acting fragment such as AOD-9604 may be more appropriate than an incretin agonist for certain adipocyte-culture endpoints.
Research use only. All information on this page is provided strictly for in-vitro and laboratory research reference. Nothing in this article is medical, therapeutic, dosing, or performance advice for human or veterinary use.
